Drug Product Leader within Cell and Gene Technical Development
Dr. Magdalena Obarzanek-Fojt is currently Drug Product Leader within Cell and Gene Technical Development at Novartis. She formerly worked at EMPA – the Swiss Federal Laboratories for Materials Science and Technology in St. Gallen, Switzerland.
Her main expertise are:
•Pharmaceutical development for cell and gene
•Cell and molecular biology
After graduating from the University of Life Sciences in Poznan, Poland in 2005, she obtained a Postgraduate Fellowship at ETH Zurich, Switzerland, where she deepened her knowledge in molecular biology. After that, she obtained a Doctoral Fellowship at University of Lausanne, Switzerland, where she further specialized in molecular biology of the human cell and she developed a model system for rare skin genetic disorder using lentiviral vectors.
During her Post-Doctoral training at EMPA, she worked in multiple projects related to tissue engineering, 3D in vitro systems for drug testing; foreign body response to drug delivery biodegradable microparticles, hydrogels and carbon-nanotubes based biomaterials.
After joining Novartis in 2015, she focused on cell and viral-vector final drug products and formulation development and she contributed to multiple CGT IND/IMPD filling, including BLA filing for Kymriah, the first approved ATMPs in the US.
Magdalena is a member of APV Drug Delivery Focus Group, as an expert for ATMPs.